Forty-year journey of angiogenesis translational research

Forty years ago, Judah Folkman predicted that tumor growth is dependent on angiogenesis and that inhibiting this process might be a new strategy for cancer therapy. This hypothesis formed the foundation of a new field of research that represents an excellent example of how a groundbreaking scientifi...

Full description

Saved in:
Bibliographic Details
Published in:Science translational medicine 2011-12, Vol.3 (114), p.114rv3-114rv3
Main Authors: Cao, Yihai, Arbiser, Jack, D'Amato, Robert J, D'Amore, Patricia A, Ingber, Donald E, Kerbel, Robert, Klagsbrun, Michael, Lim, Sharon, Moses, Marsha A, Zetter, Bruce, Dvorak, Harold, Langer, Robert
Format: Article
Language:English
Subjects:
Biomarkers
Fibroblast Growth Factor 2 - physiology
Humans
Medicin och hälsovetenskap
Neoplasms - blood supply
Neovascularization, Pathologic - drug therapy
TECHNOLOGY
TEKNIKVETENSKAP
Vascular Endothelial Growth Factor A - physiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Forty years ago, Judah Folkman predicted that tumor growth is dependent on angiogenesis and that inhibiting this process might be a new strategy for cancer therapy. This hypothesis formed the foundation of a new field of research that represents an excellent example of how a groundbreaking scientific discovery can be translated to yield benefits for patients. Today, antiangiogenic drugs are used to treat human cancers and retinal vascular diseases. Here, we guide readers through 40 years of angiogenesis research and discuss challenges of antiangiogenic therapy.
ISSN:1946-6234
1946-6242
1946-6242
DOI:10.1126/scitranslmed.3003149